🌵 Editor's Note:

This newsletter was created with significant AI assistance—not by preference (though a little AI imaging is fun), but by practical necessity. CIDP has required me to adapt in countless ways, and AI tools are simply another adaptation that allows us to continue serving our community with the depth and frequency you deserve.

Here's the irony: while I'm using AI to maintain our publications, concerns about AI overuse dominate the headlines. But let's remember—AI is a tool. Like a hammer or my wide ugly shoes, it's about adaptation and appropriate use. When done ethically, what really matters is the outcome.

And the outcomes in rare disease research are remarkable. AI-assisted researchers are achieving breakthroughs at unprecedented speed. What once required years of analysis now takes months. The advances in this issue—from FDA policy changes to new treatments—are arriving faster than ever before.

This is why we're here: to ensure Texas families have access to these developments as they happen.

This issue covers critical September updates, including the FDA's new fast-track pathway for ultra-rare diseases, three landmark treatment approvals, and NIH's discovery of a novel neurological condition. These represent real, meaningful progress for families confronting rare neurodegenerative diseases.

⏱ Read time: 4 minutes

📋 Issue Summary

🧬 FDA’s Accelerated Approval Process for Ultra-Rare Diseases
On September 3, the FDA implemented the Rare Disease Evidence Principles (RDEP), allowing treatment approvals for diseases affecting fewer than 1,000 individuals in the U.S. based on a single robust clinical trial supported by confirmatory evidence. This policy addresses challenges in conducting large-scale trials for ultra-rare conditions.

Eligible diseases must progress rapidly, lack existing therapies, and have known genetic defects directly targeted by therapies.

Texas institutions such as Texas Children’s Hospital, UT Southwestern, and Houston Methodist are positioned to benefit, potentially reducing approval timelines substantially.

📞 Patients and clinicians are encouraged to consult genetic counselors regarding eligibility for treatments under RDEP.

Expanded CIDP Treatment Options
Recent advances are diversifying immunoglobulin therapies for chronic inflammatory demyelinating polyneuropathy (CIDP). Takeda’s HyQvia now holds Canadian authorization as the first subcutaneous Ig maintenance therapy offering flexible dosing every two, three, or four weeks. Meanwhile, Takeda’s GAMMAGARD LIQUID ERC has secured U.S. FDA approval as a ready-to-use 10% liquid immunoglobulin for primary immunodeficiency, simplifying administration without reconstitution. Complement inhibitors like riliprubart complement these options, demonstrating 88% patient improvement in trials. Together, these products expand home-based care, reduce hospital visits, and personalize CIDP management—enhancing quality of life for patients.
Discover details: https://www.specialtypharmacycontinuum.com/Review-Articles/Article/10-25/A-Deeper-Dive-Into-The-New-IG-Products/7844

🔬 NIH Identification of a Novel Neurological Disorder Associated with ATG4D
NIH researchers have characterized a previously unrecognized neurological condition linked to pathogenic variants in the ATG4D gene, essential for autophagy — the intracellular recycling mechanism crucial for neuron function and survival.

This discovery, bridging veterinary studies on the Lagotto Romagnolo dog breed with human medicine, advances understanding of neurodegenerative mechanisms and may inform Alzheimer’s research.

⚠️ Healthcare providers should consider comprehensive genetic panels including autophagy-related genes when evaluating patients with unexplained motor and speech impairments.

🏥 Clinical Trial Centers in Texas

🗣️ Community Perspective
"Receiving a Barth syndrome diagnosis was difficult, but recent treatment advances offer renewed hope. Texas NeuroRare’s updates keep us informed and connected." — Marcus F., Houston

"The FDA’s accelerated approval pathway gives optimism for improved treatment access for my daughter." — Anonymous, Dallas

📅 Upcoming Events

🎯 Recommended Actions

📚 Glossary

🤝 Partnership Opportunities
Texas NeuroRare invites collaboration with organizations to enhance education and support for Texas families affected by rare neurological diseases.

Stay connected at [email protected]. © 2025 Texas NeuroRare - Bi-Weekly Publication